¼¼°èÀÇ ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå
Unit Dose Manufacturing
»óǰÄÚµå : 1777644
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 375 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,229,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,687,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀåÀº 2030³â±îÁö 1,348¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 767¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀåÀº 2024-2030³â¿¡ CAGR 9.9%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 1,348¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®Çϰí ÀÖ´Â ºÎ¹®ÀÇ ÇϳªÀÎ ÀÎÇϿ콺´Â CAGR 8.5%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 817¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Æ¿ô¼Ò½Ì ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 12.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 209¾ï ´Þ·¯, Áß±¹Àº CAGR 13.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀåÀº 2024³â¿¡ 209¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 272¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 13.2%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 7.2%¿Í 8.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 7.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Á¤¹Ð Åõ¿©·ÎÀÇ ÀüȯÀÌ ÀǾàǰ Æ÷ÀåÀÇ Àü¸ÁÀ» ÀçÁ¤ÀÇÇÏ´Ù?

ÀǾàǰÀÇ ¾ÈÀü¼º, Åõ¾àÀÇ Á¤È®¼º, ±ÔÁ¦ Áؼö¿¡ ´ëÇÑ Á߿伺ÀÌ °­Á¶µÇ¸é¼­ Á¦¾à ¹× ÇコÄÉ¾î ºÐ¾ß¿¡¼­ ´ÜÀ§ ¿ë·® Á¦Á¶ÀÇ Ã¤ÅÃÀÌ ºü¸£°Ô ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ´ÜÀ§ ¿ë·® Æ÷ÀåÀº °³º°ÀûÀ¸·Î Æ÷ÀåµÇ°í ¶óº§ÀÌ ºÎÂøµÈ ¾àǰÀÇ ¿ë·®À» 1ȸ¿ëÀ¸·Î ¼³°èµÇ¾î ȯÀÚÀÇ ¾ÈÀü¼ºÀ» ³ôÀ̰í Åõ¾à ¿À·ùÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Çü½ÄÀº Á¤È®ÇÑ Á¶Á¦°¡ Ä¡·á ¼º°ú Çâ»ó°ú ¾à¹° ºÎÀÛ¿ë ÃÖ¼ÒÈ­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â º´¿ø ¹× Àå±â ¿ä¾ç ȯ°æ¿¡¼­ ƯÈ÷ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ ¸° ¿î¿µ, ÀÚµ¿È­, µðÁöÅÐÈ­¸¦ Á¡Á¡ ´õ ¸¹ÀÌ µµÀÔÇϰí ÀÖ´Â °¡¿îµ¥, ´ÜÀ§ ¿ë·® Á¦Á¶´Â È¿À²ÀûÀÎ Åõ¾à °ü¸®ÀÇ ÇÙ½ÉÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. Á¦¾à»ç, ÀǾàǰ Á¦Á¶ ¼öʱâ°ü(CMO), ÀÇ·á±â°üÀº °æ±¸¿ë °íÇüÁ¦ºÎÅÍ ÁÖ»çÁ¦, ÈíÀÔÁ¦±îÁö ´Ù¾çÇÑ Á¦Çü¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ÀÚµ¿ ´ÜÀ§ ¿ë·® »ý»ê ½Ã½ºÅÛ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÌ Æ÷¸ËÀº ¹ÙÄÚµå ½ºÄµ, ÀüÀڰǰ­±â·Ï(EHR), Åõ¾à ÃßÀû ½Ã½ºÅÛ°ú ȣȯµÇ¾î ±× ¸Å·ÂÀ» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÌ ¶óº§¸µ, ÃßÀû¼º, °ø±Þ¸Á Åõ¸í¼º¿¡ ´ëÇÑ °ü¸®¸¦ °­È­ÇÏ´Â °¡¿îµ¥, ´ÜÀ§ ¿ë·® Á¦Á¶´Â Çö´ë ÀǾàǰ ¹°·ù¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

ȯÀÚ ¾ÈÀü°ú º´¿øÀÇ È¿À²¼ºÀÌ ´ÜÀ§ ¿ë·® Æ÷ÀåÀÇ ±ÞÁõ¿¡ ¹ÚÂ÷¸¦ °¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

º´¿ø, Áø·á¼Ò, ¿Ü·¡ Áø·á ¼¾ÅÍ´Â ÀÇ·á ½Ç¼ö¸¦ ÁÙÀ̰í, ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí, Åõ¾à ÇÁ·Î¼¼½º¸¦ ÃÖÀûÈ­ÇØ¾ß ÇÑ´Ù´Â ¾Ð¹ÚÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ´ÜÀ§ ¿ë·® Æ÷ÀåÀº ÀÇ·áÁøÀÇ ¼öÀÛ¾÷À» ÃÖ¼ÒÈ­Çϰí, ¸íÈ®ÇÏ°Ô ¶óº§ÀÌ ºÎÂøµÇ¾î ÀÖÀ¸¸ç, ºÎÁ¤ °³ºÀÀ» ¹æÁöÇϰí, ¹Ù·Î »ç¿ëÇÒ ¼ö ÀÖ´Â Åõ¾à ´ÜÀ§¸¦ Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¸ñÇ¥¸¦ Á÷Á¢ÀûÀ¸·Î Áö¿øÇÕ´Ï´Ù. À̴ ƯÈ÷ ÀÔ¿ø º´µ¿À̳ª ÀÀ±Þ½Ç µî ½Ã°£°úÀÇ ½Î¿òÀÎ ¾à¹° Åõ¿©¿Í Á÷¿øµéÀÇ ¾÷¹« ºÎ´ãÀÌ Å« ¹®Á¦°¡ µÇ´Â ´ë·®ÀÇ ¾à¹°À» Ãë±ÞÇϴ ȯ°æ¿¡¼­ Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ ´ÜÀ§ ¿ë·® Çü½ÄÀº ÀÇ·áÁøÀÌ ¹ÙÄڵ带 »ç¿ëÇÏ¿© Á¤È®ÇÑ ¿ë·®À» ½Å¼ÓÇÏ°Ô È®ÀÎÇÒ ¼ö ÀÖÀ¸¸ç, ±³Â÷ ¿À¿° ¹× ¿ÀÅõ¾à °¡´É¼ºÀ» ³·Ãâ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Åõ¾à ¿ä¹ýÀÌ Á¡Á¡ ´õ °³ÀÎÈ­µÇ°í º¹ÀâÇØÁü¿¡ µû¶ó ´ÜÀ§ ¿ë·® ½Ã½ºÅÛÀº ´ë·® Æ÷ÀåÀ̳ª ¼öÀÛ¾÷¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°íµµ °³º° ȯÀÚÀÇ Çʿ信 µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖ´Â À¯¿¬¼ºÀ» Á¦°øÇÕ´Ï´Ù. Á¤È®ÇÑ Åõ¾àÀÌ Æ¯È÷ Áß¿äÇÑ ¼Ò¾Æ ¹× ³ëÀÎ ÀÇ·á¿¡¼­ ´ÜÀ§ ¿ë·® ¼Ö·ç¼ÇÀº ¾ÈÀü¼ºÀ» Çâ»ó½Ã۰í, ±ÔÁ¤ Áؼö¸¦ °£¼ÒÈ­Çϸç, À§ÇèÀ» ÁÙÀÔ´Ï´Ù. ¶ÇÇÑ ´ÜÀ§ ¿ë·® ¸ðµ¨Àº Àç°í °ü¸® ¹× Æó±â¹° °¨¼Ò¸¦ Áö¿øÇÏ¿© º´¿øÀÌ ÀÇ·áÀÇ ÁúÀ» À¯ÁöÇϸ鼭 ÀǾàǰ ºñ¿ëÀ» °ü¸®ÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ º¹ÇÕÀûÀÎ ÀåÁ¡À¸·Î ÀÎÇØ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ±Þ¼º±â ¹× ¸¸¼º±â Ä¡·á Á¦°ø ¸ðµ¨¿¡ ´ÜÀ§ ¿ë·® Çü½ÄÀ» ÅëÇÕÇϵµ·Ï Àå·ÁÇϰí ÀÖÀ¸¸ç, ±× °á°ú Àüü ÀÇ·á ±â°ü¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

ÀÚµ¿È­¿Í ½º¸¶Æ® ÆÐŰ¡ ±â¼úÀÌ ´ÜÀ§ ¿ë·® Á¦Á¶¸¦ ¹Ù²Ü ¼ö Àִ°¡?

±â¼ú Çõ½ÅÀº ´ÜÀ§ ¿ë·® Á¦Á¶ÀÇ ±â´ÉÀ» È®ÀåÇϰí Çö´ëÈ­ÇÏ´Â µ¥ ÀÖÀ¸¸ç, Çõ½ÅÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­°¡ ÃÖÀü¼±¿¡ ÀÖÀ¸¸ç, ÇöÀç Æ÷Àå ¶óÀÎÀº ÃÖ¼ÒÇÑÀÇ Àη °³ÀÔÀ¸·Î °³º° ´ÜÀ§ÀÇ °í¼Ó ÃæÀü, ¶óº§¸µ, ¹ÐºÀ ¹× °Ë»ç¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ·Îº¿ ½Ã½ºÅÛ°ú AI Áö¿ø À̹ÌÁö °Ë»ç ÅøÀº ÀϰüµÈ ǰÁú°ü¸®¸¦ º¸ÀåÇϰí, ¸ðµâ½Ä »ý»ê ¶óÀÎÀº ´Ù¾çÇÑ Á¦Çü ¹× Æ÷Àå »ç¾ç¿¡ ´ëÀÀÇϱâ À§ÇÑ ½Å¼ÓÇÑ À籸¼ºÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. RFID ű×, QRÄÚµå, ½Ã°£-¿Âµµ Ç¥½Ã±â µî ½º¸¶Æ® ÆÐŰ¡ ±â¼úµµ ´ÜÀ§ ¿ë·® Çü½Ä¿¡ ÅëÇÕµÇ¾î °ø±Þ¸Á Àüü¿¡ °ÉÃÄ ½Ç½Ã°£ ÃßÀû ¹× È®ÀÎÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â´ÉÀº ȯÀÚ ¾ÈÀü¼ºÀ» ³ôÀ̰í, Àç°í °¡½Ã¼ºÀ» Çâ»ó½Ã۸ç, À§Á¶ ¹æÁö ±ÔÁ¤À» ÁؼöÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. º´¿ø EHR ¹× ¾à±¹ °ü¸® ¼ÒÇÁÆ®¿þ¾î¿ÍÀÇ µðÁöÅÐ ÅëÇÕÀ» ÅëÇØ ó¹æ, Á¶Á¦, °ü¸®ÀÇ ¿øÈ°ÇÑ ¿¬°è°¡ °¡´ÉÇØÁ® ½Ç¼ö¸¦ ÁÙÀ̰í È¿À²¼ºÀ» ´õ¿í ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. Áö¼Ó°¡´É¼º Ãø¸é¿¡¼­ Á¦Á¶¾÷ü´Â »ýºÐÇØ¼º Çʸ§°ú ÀçȰ¿ë °¡´ÉÇÑ Àç·á¸¦ ã°í ´ÜÀ§ ¿ë·® Æ÷ÀåÀÌ È¯°æ ¸ñÇ¥¿¡ ºÎÇÕÇϵµ·Ï ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ´ÜÀ§ ¿ë·® Á¦Á¶¸¦ º¸´Ù ÀûÀÀ·Â ÀÖ°í È¿À²ÀûÀ̸ç Áö´ÉÀûÀ¸·Î ¸¸µé¾î Á¦¾àȸ»ç¿Í ÇコÄÉ¾î ½Ã½ºÅÛÀÌ ¾ÈÀü¼º, ÃßÀû¼º, ¿î¿µ ¿ì¼ö¼º¿¡ ´ëÇÑ ÁøÈ­ÇÏ´Â ±â´ë¿¡ ºÎÀÀÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

¼¼°è ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ÅëÇÕ, ÁøÈ­ÇÏ´Â ÀÇ·á °üÇà, ±ÔÁ¦ ¿ªÇÐ, ȯÀÚ ¾ÈÀüÀÇ Çʿ伺°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ´Â ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÇÙ½É ¼ºÀå ¿äÀÎÀº Á¤È®ÇÑ Åõ¾à°ú ÃßÀû °¡´ÉÇÑ Á¶Á¦°¡ °¡Àå ÇÊ¿äÇÑ º´¿ø ¹× Àå±â ¿ä¾ç ȯ°æ¿¡¼­ ½Ç¼ö ¾ø´Â ÀÚµ¿ Åõ¾àÀ¸·Î ÀüȯÇϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¶ÇÇÑ ¿Ü·¡ ȯÀÚ ¹× ÀçÅÃÄ¡·áÀÇ È®´ë´Â ȯÀÚ¿Í °£º´ÀÎÀÇ ¹ø°Å·Î¿òÀ» ÁÙ¿©ÁÖ´Â Æí¸®ÇÏ°í °è·®È­µÈ ÀÏȸ¿ë Åõ¾à Çü½Ä¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦¾à»çµéÀº ƯÈ÷ À§Çèµµ°¡ ³ôÀº ´ë·® ÀǾàǰÀÇ °æ¿ì, ³»ºÎ ¾÷¹«¿¡ °úµµÇÑ ºÎ´ãÀ» ÁÖÁö ¾Ê°í ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ ´ÜÀ§ ¿ë·® »ý»êÀ» Àü¹®À¸·Î ÇÏ´Â CMO¿ÍÀÇ Á¦ÈÞ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ƯÈ÷ ºÏ¹Ì¿Í À¯·´¿¡¼­ ÀǾàǰ ¶óº§¸µ, ¿¬¼Ó¼º ¹× ¾ÈÀü Æ÷Àå¿¡ ´ëÇÑ ±ÔÁ¦ Àǹ«È­·Î ÀÎÇØ äÅÃÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² Æ÷Àå ÀÚµ¿È­, ½º¸¶Æ® ÃßÀû ¹× µ¥ÀÌÅÍ ÅëÇÕÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ È®À强ÀÌ Çâ»óµÇ°í ´ÜÀ§ ¿ë·® »ý»êÀÌ ´õ ¸¹Àº Á¦¾àȸ»ç¿¡¼­ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÇ·á±â°üÀÇ ºñ¿ë È¿À²¼º°ú Æó±â¹° °¨¼Ò¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °Íµµ Áß¿äÇÑ ¿äÀÎÀ̸ç, ´ÜÀ§ ¿ë·® Æ÷ÀåÀº Àç°í °ü¸®¿Í ÀÚ¿ø ÃÖÀûÈ­¿¡ È¿°úÀûÀÎ °ÍÀ¸·Î ÀÔÁõµÇ¾ú½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ º¸´Ù ¾ÈÀüÇϰí È¿À²ÀûÀÎ ¾à¹°Àü´Þ ¸ðµ¨À» Ãß±¸ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ÈûµéÀÌ Á¾ÇÕÀûÀ¸·Î ¼¼°è ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¼Ò½Ì(ÀÎÇϿ콺, ¾Æ¿ô¼Ò½Ì); Á¦Ç°(¾×ü ´ÜÀ§ ¿ë·®, °íü ´ÜÀ§ ¿ë·®, ±âŸ); ÃÖÁ¾ »ç¿ë(µ¶¸³ ¾à±¹, Àå±â¿ä¾ç½Ã¼³, º´¿ø, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Unit Dose Manufacturing Market to Reach US$134.8 Billion by 2030

The global market for Unit Dose Manufacturing estimated at US$76.7 Billion in the year 2024, is expected to reach US$134.8 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. In-house, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$81.7 Billion by the end of the analysis period. Growth in the Outsourcing segment is estimated at 12.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.9 Billion While China is Forecast to Grow at 13.2% CAGR

The Unit Dose Manufacturing market in the U.S. is estimated at US$20.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$27.2 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Unit Dose Manufacturing Market - Key Trends & Drivers Summarized

Is the Shift Toward Precision Dosing Redefining the Pharmaceutical Packaging Landscape?

The rising emphasis on medication safety, dosing accuracy, and regulatory compliance is rapidly propelling the adoption of unit dose manufacturing across pharmaceutical and healthcare sectors. Unit dose packaging involves individually packaged and labeled doses of medications, typically designed for single-use, which enhances patient safety and reduces the risk of medication errors. This format has become especially crucial in hospital and long-term care settings where accurate dispensing plays a critical role in improving treatment outcomes and minimizing adverse drug events. With healthcare systems around the world increasingly embracing lean operations, automation, and digitization, unit dose manufacturing is gaining traction as a cornerstone of efficient medication management. Pharmaceutical companies, contract manufacturing organizations (CMOs), and healthcare institutions are investing in automated unit dose production systems that can handle diverse dosage forms-ranging from oral solids to injectables and inhalables. The format’s compatibility with barcode scanning, electronic health records (EHRs), and medication tracking systems further enhances its appeal. As regulatory bodies tighten controls around labeling, traceability, and supply chain transparency, unit dose manufacturing is emerging as an essential component of modern pharmaceutical logistics.

Why Are Patient Safety and Hospital Efficiency Fueling the Surge in Unit Dose Packaging?

Hospitals, clinics, and ambulatory care centers are under increasing pressure to reduce medical errors, streamline workflow, and optimize medication administration processes. Unit dose packaging directly supports these goals by providing clearly labeled, tamper-evident, ready-to-use medication units that minimize manual handling by healthcare providers. This is particularly significant in high-volume settings like inpatient wards and emergency rooms, where time-sensitive medication administration and staff workload are major concerns. Unit dose formats also allow healthcare staff to quickly verify correct dosages using barcodes, reducing the potential for cross-contamination or incorrect administration. Moreover, as medication regimens become increasingly personalized and complex, unit dose systems offer the flexibility to tailor treatments to individual patient needs without reliance on bulk packaging or manual preparation. In pediatric and geriatric care-where accurate dosing is especially critical-unit dose solutions improve safety, simplify compliance, and lower risk. Additionally, the unit dose model supports inventory control and waste reduction, offering hospitals a way to manage pharmaceutical costs while maintaining quality of care. These combined benefits are prompting healthcare providers to integrate unit dose formats into both acute and chronic care delivery models, thereby accelerating demand across institutional healthcare settings.

Can Automation and Smart Packaging Technologies Transform Unit Dose Manufacturing?

Technological innovation is playing a transformative role in scaling and modernizing unit dose manufacturing capabilities. Automation is at the forefront, with packaging lines now capable of high-speed filling, labeling, sealing, and inspection of individual units with minimal human intervention. Robotic systems and AI-enabled vision inspection tools ensure consistent quality control, while modular production lines allow rapid reconfiguration to accommodate various drug forms and packaging specifications. Smart packaging technologies are also being incorporated into unit dose formats, including RFID tags, QR codes, and time-temperature indicators, which enable real-time tracking and verification throughout the supply chain. These features enhance patient safety, improve inventory visibility, and support compliance with anti-counterfeiting regulations. Digital integration with hospital EHRs and pharmacy management software allows for seamless alignment between prescribing, dispensing, and administration, further reducing errors and increasing efficiency. On the sustainability front, manufacturers are exploring biodegradable films and recyclable materials to align unit dose packaging with environmental goals. These advancements are making unit dose manufacturing more adaptable, efficient, and intelligent-helping pharmaceutical companies and healthcare systems meet evolving expectations for safety, traceability, and operational excellence.

What Is Driving the Growth of the Global Unit Dose Manufacturing Market?

The growth in the unit dose manufacturing market is driven by several factors closely tied to technology integration, evolving healthcare practices, regulatory dynamics, and patient safety imperatives. A central growth driver is the global shift toward error-free, automated medication administration in hospitals and long-term care settings, where the need for accurate dosing and traceable dispensing is paramount. The expansion of outpatient and home healthcare services is also fueling demand for convenient, pre-measured, single-use medication formats that reduce complexity for patients and caregivers. Pharmaceutical manufacturers are increasingly partnering with CMOs specializing in unit dose production to meet demand without overburdening internal operations, especially for high-risk and high-volume drugs. Regulatory mandates on drug labeling, serialization, and safety packaging are further accelerating adoption, particularly in North America and Europe. In parallel, technological advances in packaging automation, smart tracking, and data integration are improving scalability and making unit dose manufacturing accessible to a wider range of pharmaceutical firms. Rising focus on cost efficiency and waste reduction in institutional settings is another key factor, with unit dose packaging proving effective in inventory control and resource optimization. As health systems pursue safer, more efficient medication delivery models, these forces are collectively propelling sustained growth in the global unit dose manufacturing market.

SCOPE OF STUDY:

The report analyzes the Unit Dose Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Sourcing (In-house, Outsourcing); Product (Liquid Unit Dose, Solid Unit Dose, Others); End-Use (Independent Pharmacies, Long Term Care Facility, Hospitals, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â